1-20 of 74
Pasi A. Jänne
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT017: FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed

Pasi A. Jänne, Kunihiko Kobayashi, Jacqulyne Robichaux, Chee Khoon Lee, Shunichi Sugawara, Tsung-Ying Yang, Tae Min Kim, Noriko Yanagitani, Sang-We Kim, Aleksandra Markovets, Preetida Bhetariya, Lynne Poole, Dana Ghiorghiu, Ryan Hartmaier, James Chih-Hsin Yang, David Planchard
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT017.
https://doi.org/10.1158/1538-7445.AM2024-CT017
Published: 05 April 2024
View article titled, Abstract CT017: FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed
Journal Articles

Abstract 2166: Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A)

Rachel E. Sanborn, Saiama N. Waqar, Byoung Chul Cho, Benjamin Besse, Koichi Goto, Yongsheng Wang, Se-Hoon Lee, Melina E. Marmarelis, Yuichiro Ohe, Dong-Wan Kim, Antonio Calles, Joel Neal, Christina S. Baik, Pasi A. Janne, Joshua C. Curtin, Bharvin Patel, Mike Gormley, S. Martin Shreeve, Joshua M. Bauml, Roland E. Knoblauch, James Chih-Hsin Yang
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2166.
https://doi.org/10.1158/1538-7445.AM2023-2166
Published: 04 April 2023
View article titled, Abstract 2166: Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A)
Journal Articles

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer

Ryohei Yoshida, Maria Saigi, Tetsuo Tani, Benjamin F. Springer, Hirofumi Shibata, Shunsuke Kitajima, Navin R. Mahadevan, Marco Campisi, William Kim, Yoshihisa Kobayashi, Tran C. Thai, Koji Haratani, Yurie Yamamoto, Shriram K. Sundararaman, Erik H. Knelson, Amir Vajdi, Israel Canadas, Ravindra Uppaluri, Cloud P. Paweletz, Juan J. Miret, Patrick H. Lizotte, Prafulla C. Gokhale, Pasi A. Jänne, David A. Barbie
Journal: Cancer Research
Cancer Res (2022) 82 (21): 4079–4092.
https://doi.org/10.1158/0008-5472.CAN-22-0770
Published: 02 November 2022
View article titled, MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer
Open the PDF for MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 2181: Genomic correlates of Metastasis in KRAS mutant lung adenocarcinoma

Daniel Boiarsky, Christine A. Lydon, Emily Chambers, Pasi A. Janne, Mark M. Awad, Eliezer M. Van Allen, David Barbie, Natalie I. Vokes
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2181.
https://doi.org/10.1158/1538-7445.AM2022-2181
Published: 15 June 2022
View article titled, Abstract 2181: Genomic correlates of Metastasis in KRAS mutant lung adenocarcinoma
Journal Articles

Abstract 333: Activity of the erythropoietin-producing hepatocellular A2 receptor (EphA2) targeting Bicycle® Toxin Conjugate (BTC™) BCY6033 in EGFR inhibitor resistant non-small lung cancer (NSCLC) patient derived xenografts

Kenneth Ngo, Elena V. Ivanova, Tyler J. Teceno, Carly Campbell, Johanna Lahdenranta, Stephen J. Blakemore, Gavin Bennett, Pasi A. Jänne, Cloud P. Paweletz, Prafulla C. Gokhale
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 333.
https://doi.org/10.1158/1538-7445.AM2022-333
Published: 15 June 2022
View article titled, Abstract 333: Activity of the erythropoietin-producing hepatocellular A2 receptor (EphA2) targeting Bicycle® Toxin Conjugate (BTC™) BCY6033 in EGFR inhibitor resistant non-small lung cancer (NSCLC) patient derived xenografts
Journal Articles

Abstract 4117: Clinicopathologic and molecular characterization of KRASG12D lung cancers

Jia Luo, Biagio Ricciuti, Joao V. Alessi, Xinan Wang, Victor Vaz, Federica Pecci, Tom Nguyen, James Lindsay, Bijaya Sharma, Kristen D. Felt, Scott J. Rodig, Mizuki H. Nishino, Lynette M. Sholl, David A. Barbie, Pasi A. Jänne, Mark M. Awad
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4117.
https://doi.org/10.1158/1538-7445.AM2022-4117
Published: 15 June 2022
View article titled, Abstract 4117: Clinicopathologic and molecular characterization of KRAS<sup>G12D</sup> lung cancers
Journal Articles

A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non–Small Cell Lung Cancer

Jieun Son, Jaebong Jang, Tyler S. Beyett, Yoonji Eum, Heidi M. Haikala, Alyssa Verano, Mika Lin, John M. Hatcher, Nicholas P. Kwiatkowski, Pinar Ö. Eser, Michael J. Poitras, Stephen Wang, Man Xu, Prafulla C. Gokhale, Michael D. Cameron, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne
Journal: Cancer Research
Cancer Res (2022) 82 (8): 1633–1645.
https://doi.org/10.1158/0008-5472.CAN-21-2693
Published: 15 April 2022
View article titled, A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non–Small Cell Lung Cancer
Open the PDF for A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody–Drug Conjugate HER3–DXd

Heidi M. Haikala, Timothy Lopez, Jens Köhler, Pinar O. Eser, Man Xu, Qing Zeng, Tyler J. Teceno, Kenneth Ngo, Yutong Zhao, Elena V. Ivanova, Arrien A. Bertram, Brittaney A. Leeper, Emily S. Chambers, Anika E. Adeni, Luke J. Taus, Mari Kuraguchi, Paul T. Kirschmeier, Channing Yu, Yoshinobu Shiose, Yasuki Kamai, Yang Qiu, Cloud P. Paweletz, Prafulla C. Gokhale, Pasi A. Jänne
Journal: Cancer Research
Cancer Res (2022) 82 (1): 130–141.
https://doi.org/10.1158/0008-5472.CAN-21-2426
Published: 04 January 2022
View article titled, EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody–Drug Conjugate HER3–DXd
Open the PDF for EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody–Drug Conjugate HER3–DXd in another window
Includes: Supplementary data
Journal Articles

Abstract CT127: Tumor response and MET-detection methods exploratory biomarker analysis of Part B of the Ph 1b TATTON study

Ryan Hartmaier, Ji-Youn Han, Byoung Chul Cho, Aleksandra Markovets, Nisha Kurian, Mireille Cantarini, Pasi A. Janne
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT127.
https://doi.org/10.1158/1538-7445.AM2021-CT127
Published: 01 July 2021
View article titled, Abstract CT127: Tumor response and MET-detection methods exploratory biomarker analysis of Part B of the Ph 1b TATTON study
Journal Articles

Abstract LB054: Confirmation of target inhibition and anti-tumor activity of the SHP2 inhibitor RMC-4630 via longitudinal analysis of ctDNA in a phase 1 clinical study

Josie L. Hayes, Marianna Koczywas, Sai-Hong Ignatius Ou, Pasi A. Janne, Jose M. Pacheco, Susanna Ulahannan, Judy S. Wang, Howard A. Burris, Jonathan W. Riess, Caroline McCoach, Michael S. Gordon, Anna Capasso, Ariel Chen, Richa Dua, Bojena Bitman, Martha Guerra, Hongfang Wang, Xiaolin Wang, Eric Haura
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): LB054.
https://doi.org/10.1158/1538-7445.AM2021-LB054
Published: 01 July 2021
View article titled, Abstract LB054: Confirmation of target inhibition and anti-tumor activity of the SHP2 inhibitor RMC-4630 via longitudinal analysis of ctDNA in a phase 1 clinical study
Journal Articles

Abstract 490: A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC

Biagio Ricciuti, Kathryn C. Arbour, Navin R. Mahadevan, Joao V. Alessi, James Lindsay, Renato Umeton, Rileen Sinha, Amir Hoojghan, Natalie Vokes, Gonzalo Recondo, Giuseppe Lamberti, Andrew Polio1, Hira Rizvi, Giulia Leonardi, Andrew J. Plodkowski, Kristen Felt, Bijaya Sharma, Michael Y. Tolstorukov, Pasi A. Janne, Eliezer M. Van Allen, Lynette M. Sholl, Scott J. Rodig, Matthew D. Hellmann, Mark M. Awad
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 490.
https://doi.org/10.1158/1538-7445.AM2021-490
Published: 01 July 2021
View article titled, Abstract 490: A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC
Journal Articles

Abstract CT024: Acquired resistance in patients with EGFRm NSCLC following treatment with osimertinib plus savolitinib in the Ph1b TATTON study Parts B and D

Aleksandra Markovets, Ji-Youn Han, Byoung Chul Cho, Mireille Cantarini, Pasi A. Janne, Ryan Hartmaier
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT024.
https://doi.org/10.1158/1538-7445.AM2021-CT024
Published: 01 July 2021
View article titled, Abstract CT024: Acquired resistance in patients with EGFRm NSCLC following treatment with osimertinib plus savolitinib in the Ph1b TATTON study Parts B and D
Journal Articles

Abstract LB001: Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers

Marianna Koczywas, Eric Haura, Pasi A. Janne, Jose M. Pacheco, Susanna Ulahannan, Judy S. Wang, Howard A. Burris, Jonathan W. Riess, Caroline McCoach, Michael S. Gordon, Anna Capasso, Richa Dua, Zhengping Wang, Ariel Chen, Josie Hayes, Luxi Yang, Serena Masciari, Xiaolin Wang, S Ignatius Ou
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): LB001.
https://doi.org/10.1158/1538-7445.AM2021-LB001
Published: 01 July 2021
View article titled, Abstract LB001: Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers
Journal Articles

Abstract LB050: Modulation of innate and adaptive immunity in blood and tumor of patients receiving the SHP2 inhibitor RMC-4630

Ariel Yung-Chia Chen, Eric Haura, Jose Pacheco, Marianna Koczywas, Michael Gordon, Susanna Ulahannan, Howard A. Burris, Sai-Hong Ignatius Ou, Judy S. Wang, Jonathan W. Riess, Caroline McCoach, Anna Capasso, Elsa Quintana, Josie Hayes, Richa Dua, Bojena Bitman, Martha Guerra, Hongfang Wang, Xiaolin Wang, Pasi A. Janne
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): LB050.
https://doi.org/10.1158/1538-7445.AM2021-LB050
Published: 01 July 2021
View article titled, Abstract LB050: Modulation of innate and adaptive immunity in blood and tumor of patients receiving the SHP2 inhibitor RMC-4630
Journal Articles

KRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non–Small Cell Lung Cancer

Zhi-Wei Zhou, Chiara Ambrogio, Asim K. Bera, Qing Li, Xing-Xiao Li, Lianbo Li, Jieun Son, Sudershan Gondi, Jiaqi Li, Emily Campbell, Hua Jin, Jeffrey J. Okoro, Cheng-Xiong Xu, Pasi A. Janne, Kenneth D. Westover
Journal: Cancer Research
Series: Author Choice
Cancer Res (2020) 80 (17): 3719–3731.
https://doi.org/10.1158/0008-5472.CAN-20-0448
Published: 02 September 2020
View article titled, KRAS<sup>Q61H</sup> Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non–Small Cell Lung Cancer
Open the PDF for KRAS<sup>Q61H</sup> Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 5192: EGFR inhibition enhances the cellular uptake and antitumor activity of the novel HER3 antibody drug conjugate U3-1402

Heidi M. Haikala, Jens Köhler, Timothy Lopez, Pinar Eser, Man Xu, Channing Yu, Yoshinobu Shiose, Yang Qiu, Prafulla Gokhale, Pasi A. Jänne
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5192.
https://doi.org/10.1158/1538-7445.AM2020-5192
Published: 15 August 2020
View article titled, Abstract 5192: EGFR inhibition enhances the cellular uptake and antitumor activity of the novel HER3 antibody drug conjugate U3-1402
Journal Articles

CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC

Jeffrey H. Becker, Yandi Gao, Margaret Soucheray, Ines Pulido, Eiki Kikuchi, María L. Rodríguez, Rutu Gandhi, Aranzazu Lafuente-Sanchis, Miguel Aupí, Javier Alcácer Fernández-Coronado, Paloma Martín-Martorell, Antonio Cremades, José M. Galbis-Caravajal, Javier Alcácer, Camilla L. Christensen, Patricia Simms, Ashley Hess, Hajime Asahina, Michael P. Kahle, Fatima Al-Shahrour, Jeffrey A. Borgia, Agustín Lahoz, Amelia Insa, Oscar Juan, Pasi A. Jänne, Kwok-Kin Wong, Julian Carretero, Takeshi Shimamura
Journal: Cancer Research
Cancer Res (2019) 79 (17): 4439–4452.
https://doi.org/10.1158/0008-5472.CAN-19-0024
Published: 03 September 2019
View article titled, CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
Open the PDF for CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC in another window
Includes: Supplementary data
Journal Articles

Abstract 3783: Effective MEK inhibitor combinations to target tumor heterogeneity in EGFR mutant transformed SCLC

Atsuko Ogino, Xinmeng Jasmine Mu, Mika Lin, Antonio Calles, Stephen Wang, Man Xu, Lynette M. Scholl, Geoffrey R. Oxnard, Paul Kirschmeier, Pasi A. Jänne
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3783.
https://doi.org/10.1158/1538-7445.AM2019-3783
Published: 01 July 2019
View article titled, Abstract 3783: Effective MEK inhibitor combinations to target tumor heterogeneity in <em>EGFR</em> mutant transformed SCLC
Journal Articles

Abstract 1374: Building an effective concordance study: Plasma Next Generation Sequencing (NGS) for oncogenic fusion detection in non-small cell lung carcinoma (NSCLC)

Julianna G. Supplee, Marina S. Milan, Kristy T. Potts, Lynette M. Sholl, Tristan S. Shaffer, Lee P. Lim, Pasi A. Janne, Geoffrey R. Oxnard, Cloud P. Paweletz
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1374.
https://doi.org/10.1158/1538-7445.AM2019-1374
Published: 01 July 2019
View article titled, Abstract 1374: Building an effective concordance study: Plasma Next Generation Sequencing (NGS) for oncogenic fusion detection in non-small cell lung carcinoma (NSCLC)
Journal Articles

Abstract 452: Salivary HPV cell free DNA levels predict locoregional disease burden and response in oropharyngeal cancer

Glenn J. Hanna, Christie J. Lau, Umair Mahmood, Robert I. Haddad, Cloud P. Paweletz, Pasi A. Janne
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 452.
https://doi.org/10.1158/1538-7445.AM2019-452
Published: 01 July 2019
View article titled, Abstract 452: Salivary HPV cell free DNA levels predict locoregional disease burden and response in oropharyngeal cancer